CELL & GENE CAPACITY UPDATE VIDEOS

22:22 ProBio Capabilities Update October 2026: Cell & Gene Therapy
ProBio Capabilities Update October 2026: Cell & Gene Therapy

In vivo CAR-T therapies could expand access and lower costs by eliminating ex vivo manufacturing. Robust CMC strategies, vector design, and analytics are key to accelerating clinical translation.

17:13 Andelyn Biosciences Capabilities Update October 2026: Cell & Gene Therapy
Andelyn Biosciences Capabilities Update October 2026: Cell & Gene Therapy

Achieving commercial readiness for AAV gene therapies starts early. Prioritizing assay lock, process qualification, and supply chain security reduces risk and supports reliable patient supply.

19:29 Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy
Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy

A global CDMO specializing in cell and gene therapies, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.

22:28 Lonza Capabilities Update March 2026: Cell & Gene Therapy
Lonza Capabilities Update March 2026: Cell & Gene Therapy

A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

17:22 Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy
Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy

A translational CDMO approach integrates development, analytics, and GMP manufacturing to streamline cell and gene therapy advancement from early research through scalable clinical production.

17:16 Comprehensive Cell Solutions Capabilities Update March 2026: Cell & Gene Therapy
Comprehensive Cell Solutions Capabilities Update March 2026: Cell & Gene Therapy

An integrated draw‑to‑thaw CDMO model connecting donor sourcing, development, GMP manufacturing, and cryogenic storage to streamline workflows, strengthen quality control, and speed clinical readiness.

9:57 ElevateBio OPCU March 26
ElevateBio Capabilities Update March 2026: Cell & Gene Therapy

Learn how to embed process development expertise early and continuously to eliminate knowledge gaps, reduce risk, and ensure consistent, high-quality execution from transfer through manufacturing.

15:56 Andelyn CGT OPCU Oct 2025
Andelyn Biosciences Capacity Update October 2025: Cell & Gene Therapy

A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, with emphasis on implementation based on product contact, material classification, and manufacturing stage.

Agenda & Presenter Details

Visit our registration pages to see the current agenda and our list of presenting sponsors.

How can we help?

Are you a supplier looking to present at our next event?

Become A Presenter